These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33733058)

  • 21. HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry.
    Wei C; Wan L; Yan Q; Wang X; Zhang J; Yang X; Zhang Y; Fan C; Li D; Deng Y; Sun J; Gong J; Yang X; Wang Y; Wang X; Li J; Yang H; Li H; Zhang Z; Wang R; Du P; Zong Y; Yin F; Zhang W; Wang N; Peng Y; Lin H; Feng J; Qin C; Chen W; Gao Q; Zhang R; Cao Y; Zhong H
    Nat Metab; 2020 Dec; 2(12):1391-1400. PubMed ID: 33244168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting intracellular Neu1 for coronavirus infection treatment.
    Yang D; Wu Y; Turan I; Keil J; Li K; Chen MH; Liu R; Wang L; Sun XL; Chen GY
    iScience; 2023 Feb; 26(2):106037. PubMed ID: 36714013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sphingolipids as Modulators of SARS-CoV-2 Infection.
    Törnquist K; Asghar MY; Srinivasan V; Korhonen L; Lindholm D
    Front Cell Dev Biol; 2021; 9():689854. PubMed ID: 34222257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible therapeutic targets for SARS-CoV-2 infection and COVID-19.
    Khan N; Kumar N; Geiger JD
    J Allergy Infect Dis; 2021; 2(3):75-83. PubMed ID: 37564275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulated lysosomal exocytosis mediates cancer progression.
    Machado E; White-Gilbertson S; van de Vlekkert D; Janke L; Moshiach S; Campos Y; Finkelstein D; Gomero E; Mosca R; Qiu X; Morton CL; Annunziata I; d'Azzo A
    Sci Adv; 2015 Dec; 1(11):e1500603. PubMed ID: 26824057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of selectivity of the SARS-CoV-2 virus for human genetic profiles in susceptibility and resistance to COVID-19.
    Khan FA
    New Microbes New Infect; 2020 Jul; 36():100697. PubMed ID: 32483490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders.
    Pieroni M; Pieruzzi F; Mignani R; Graziani F; Olivotto I; Riccio E; Ciabatti M; Limongelli G; Manna R; Bolognese L; Pisani A
    Clin Kidney J; 2021 May; 14(5):1488-1490. PubMed ID: 34221376
    [No Abstract]   [Full Text] [Related]  

  • 29. Targetable Biological Mechanisms Implicated in Emergent Psychiatric Conditions Associated With SARS-CoV-2 Infection.
    Postolache TT; Benros ME; Brenner LA
    JAMA Psychiatry; 2020 Jul; ():. PubMed ID: 32735332
    [No Abstract]   [Full Text] [Related]  

  • 30. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.
    Thompson MG; Burgess JL; Naleway AL; Tyner HL; Yoon SK; Meece J; Olsho LEW; Caban-Martinez AJ; Fowlkes A; Lutrick K; Kuntz JL; Dunnigan K; Odean MJ; Hegmann KT; Stefanski E; Edwards LJ; Schaefer-Solle N; Grant L; Ellingson K; Groom HC; Zunie T; Thiese MS; Ivacic L; Wesley MG; Lamberte JM; Sun X; Smith ME; Phillips AL; Groover KD; Yoo YM; Gerald J; Brown RT; Herring MK; Joseph G; Beitel S; Morrill TC; Mak J; Rivers P; Harris KM; Hunt DR; Arvay ML; Kutty P; Fry AM; Gaglani M
    MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(13):495-500. PubMed ID: 33793460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation study.
    Smith MK; Bikmetov R; Al Rihani SB; Deodhar M; Hafermann M; Dow P; Turgeon J; Michaud V
    Clin Transl Sci; 2021 Sep; 14(5):1799-1809. PubMed ID: 33786990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro safety "clinical trial" of the cardiac liability of drug polytherapy.
    Charrez B; Charwat V; Siemons B; Finsberg H; Miller EW; Edwards AG; Healy KE
    Clin Transl Sci; 2021 May; 14(3):1155-1165. PubMed ID: 33786981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19.
    Liu JB; Arockiaraj M; Arulperumjothi M; Prabhu S
    Int J Quantum Chem; 2021 May; 121(10):e26617. PubMed ID: 33785968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase.
    Celik I; Erol M; Duzgun Z
    Mol Divers; 2022 Feb; 26(1):279-292. PubMed ID: 33765239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis.
    Crespo-Facorro B; Ruiz-Veguilla M; Vázquez-Bourgon J; Sánchez-Hidalgo AC; Garrido-Torres N; Cisneros JM; Prieto C; Sainz J
    Front Pharmacol; 2021; 12():646701. PubMed ID: 33762960
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies.
    Kriszta G; Kriszta Z; Váncsa S; Hegyi PJ; Frim L; Erőss B; Hegyi P; Pethő G; Pintér E
    Front Pharmacol; 2021; 12():619524. PubMed ID: 33762942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics.
    Zhu H; Chen CZ; Sakamuru S; Zhao J; Ngan DK; Simeonov A; Hall MD; Xia M; Zheng W; Huang R
    Sci Rep; 2021 Mar; 11(1):6725. PubMed ID: 33762619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.
    Chenchula S; Ray A; Sadasivam B
    Drug Res (Stuttg); 2021 Jul; 71(6):295-301. PubMed ID: 33757133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential of CRISPR/Cas13 System in Treatment and Diagnosis of COVID-19.
    Khodavirdipour A; Piri M; Jabbari S; Khalaj-Kondori M
    Glob Med Genet; 2021 Mar; 8(1):7-10. PubMed ID: 33748818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19.
    Zhang X; Gao R; Zhou Z; Tang X; Lin J; Wang L; Zhou X; Shen T
    Int J Med Sci; 2021; 18(8):1866-1876. PubMed ID: 33746604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.